Clinical Scorecard: Omalizumab in the Management of Severe IgE-Mediated Food Allergies and Asthma Following Pediatric Liver Transplantation: A Case Study
At a Glance
Category
Detail
Condition
De novo post-transplant food allergy (dnPTFA) and allergic asthma
Key Mechanisms
IgE-mediated hypersensitivity, Th2 skewing due to calcineurin inhibitors, viral immune modulation
Target Population
Pediatric liver transplant recipients
Care Setting
Post-transplant follow-up in pediatric patients
Key Highlights
High prevalence of dnPTFA in pediatric liver transplant recipients (4% to 58%)
Risk factors include young age, female sex, atopy history, and immunosuppressive therapy
Omalizumab has been used off-label to manage severe asthma and dnPTFA
Patient achieved excellent asthma control and resumed a less restricted diet after omalizumab treatment
Stable liver graft function maintained over more than 5 years
Guideline-Based Recommendations
Diagnosis
Clinical evaluation of allergy symptoms post-transplant
Consideration of IgE-mediated mechanisms in allergic reactions
Management
Strict elimination of offending allergens from the diet
Consideration of omalizumab for severe cases
Monitoring & Follow-up
Regular follow-up for liver graft function and allergy symptoms
Surveillance for viral infections such as EBV and CMV
Risks
Potential for life-threatening allergic reactions
Compromised growth due to food selectivity
Patient & Prescribing Data
Pediatric patients post-liver transplantation
Omalizumab increases the threshold for clinical reactivity to food allergens
Clinical Best Practices
Maintain immunosuppression at low target levels to prevent adverse events
Monitor for signs of acute or chronic rejection through protocol biopsies
Ensure excellent medication adherence in post-transplant patients
